Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

e results led to the initiation of a Phase II liver cancer trial that is now open in the U.S., and will shortly begin enrolling patients at sites in South Korea and Canada, as well.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program against smallpox. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase II trial for primary liver cancer, demonstrated promising Pha
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 3:40 ... New York . A live webcast of ... replay will be available approximately one hour after the presentation. ...
(Date:8/4/2015)...  Intec Pharma Ltd. (the "Company") (NASDAQ: NTEC ... drugs based on its proprietary Accordion Pill platform technology, ... in the United States of ... the public of $6.00 per ordinary share, before underwriting ... being offered by the Company.  In addition, the Company ...
(Date:8/4/2015)... 4, 2015 Concord Medical Services Holdings Limited ("Concord ... management solution provider and operator of the largest network of ... , today announced it will release its financial results for ... August 17, 2015. Management will hold a conference ... a.m. EDT on August 18, 2015 (8:00 p.m. in ...
Breaking Medicine Technology:MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2
... CITY, June 23, 2011 PD-Rx Pharmaceuticals, Inc., ... the purchase of the Washington EMR, an electronic ... Washington EMR is the premier quality, low-cost ... The intuitive interface allows the physician and assistants ...
... SAN DIEGO, June 23, 2011 BioSurplus today announced ... of instruments worth over $10 million will be auctioned ... The first auction will have choice laboratory equipment ... HPLCs and Mass Specs, Molecular Devices Spectramax M5 plate ...
Cached Medicine Technology:PD-Rx Pharmaceuticals Acquires Wilson Medical's EMR 2BioSurplus Selected to Auction $10 Million in Lab Equipment 2
(Date:8/4/2015)... TX (PRWEB) , ... August 04, 2015 , ... Bayco ... factor small enough to fit, for example, on hard hats that have a flip-up ... Dual-Light Headlamp allows users to work without having to remove their headlamp when ...
(Date:8/4/2015)... Santa Barbara, CA (PRWEB) , ... August 04, ... ... if you are suffering from underarm sweat. Evolutions Medical & Day Spa in ... called miraDry, the only non-invasive, FDA cleared treatment that permanently eliminates sweat and ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... , Worldwide Power Products is expanding its reach in Texas. Effective July 1st ... Power Systems North Texas generator division. With the North Texas acquisition, Worldwide ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San ... sustainably, create new businesses, improve food access, and manage resources efficiently against the ...
(Date:8/4/2015)... , ... August 04, 2015 , ... One of the ... to discuss his new book, The Pain Antidote , which provides strategies for ... Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction with ...
Breaking Medicine News(10 mins):Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:North Texas Acquisition Press Release 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... indiscriminate antibiotic use, saying that nearly half ... issue figures on the agenda at the ... in Sydney. ,Microbiologist John Turnidge, of the ... trend of antibiotic overdose has led to an ...
... level of which is strongly suggestive of prostate cancer ... spot early signs of prostate cancer, // if any. A ... be needed for establishment of prostate cancer diagnosis in young ... ,The researchers from Duke University Medical Center analyzed more than ...
... A new study has found that awards and accomplishments could ... individual. Oscar winners have been on an average found to ... lost the race and went home and empty-handed. ... found in the latest issue of the Harvard Health Letter. ...
... principle investigator said that the new technique of in vitro ... that can enhance or block different kinds of tastes.// Researchers ... mature taste receptor cells outside the body. They have also ... period of time. This is a break through as it ...
... Cigarette smoking not only harms the teeth by way of ... need for root canal treatment, according to a new study ... Dental Research. ,"The findings substantiate what most ... Elizabeth Krall Kaye, PhD, MPH, epidemiologist at the Boston VA ...
... Koinis Mitchell, PhD, with the Bradley Hasbro Children's Research ... of asthma on children. She said that // those ... be less likely to have their asthma symptoms interfere ... related to urban scenario and facing asthma symptoms were ...
Cached Medicine News:Health News:Oscar Winners Live Longer Than Co-Competitors 2Health News:Functional Taste Cells Cultured In Vitro 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a scientifically advanced nutritional formulation that ... full body health. MacularProtect Complete-S, based ... other advanced research, delivers a diverse ... mg of FloraGLO® lutein and other ...
... PreserVision® Soft Gel Lutein patented formula is ... Lomb PreserVision® AREDS formula, with the beta-carotene ... Lutein is a carotenoid found in dark ... is highly concentrated in the macula, the ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: